1-20 of 21
Armin Leitner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Clinical Trials & Observations
Alice Fabarius, Armin Leitner, Andreas Hochhaus, Martin C. Müller, Benjamin Hanfstein, Claudia Haferlach, Gudrun Göhring, Brigitte Schlegelberger, Martine Jotterand, Andreas Reiter, Susanne Jung-Munkwitz, Ulrike Proetel, Juliana Schwaab, Wolf-Karsten Hofmann, Jörg Schubert, Hermann Einsele, Anthony D. Ho, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Gabriela M. Baerlocher, Michael Lauseker, Markus Pfirrmann, Joerg Hasford, Susanne Saussele, Rüdiger Hehlmann, for the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
Journal: Blood
Blood (2011) 118 (26): 6760–6768.
https://doi.org/10.1182/blood-2011-08-373902
Published: 2011
Journal Articles

Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

Alice Fabarius, PhD, Armin Leitner, MD, Andreas Hochhaus, MD, Martin C Müller, MD, Claudia Haferlach, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Martine Jotterand, MD, Andreas Reiter, MD, Susanne Jung-Munkwitz, MD, Ulrike Proetel, MD, Juliana Schwaab, MD, Wolf-Karsten Hofmann, Joerg E. A. Schubert, MD, Hermann Einsele, Anthony D. Ho, MD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Wolfgang Hiddemann, PhD, Gabriela M. Baerlocher, MD, Michael Lauseker, Markus Pfirrmann, PhD, Susanne Saussele, MD, Rüdiger Hehlmann, MD, Joerg Hasford, MD
Journal: Blood
Blood (2011) 118 (21): 782.
https://doi.org/10.1182/blood.V118.21.782.782
Published: 2011
Journal Articles

Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph+ Chronic Myeloid Leukemia

Mridul Agrawal, Philipp Erben, MD, Benjamin Hanfstein, MD, Armin Leitner, MD, John Reynolds, Richard C. Woodman, MD, Laura Robin, Wolf-Karsten Hofmann, MD, Andreas Hochhaus, MD, Martin C. Müller, MD
Journal: Blood
Blood (2010) 116 (21): 2283.
https://doi.org/10.1182/blood.V116.21.2283.2283
Published: 2010
Journal Articles

Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV

Martin C. Müller, MD, Andreas Hochhaus, MD, Michael Lauseker, Susanne Jung-Munkwitz, MD, Markus Pfirrmann, PhD, Armin Leitner, MD, Stefan W. Krause, MD, Nadine Pletsch, MD, Benjamin Hanfstein, MD, Susanne Schnittger, PhD, Alois Gratwohl, MD, Jörg Hasford, MD, Susanne Saussele, MD, Rüdiger Hehlmann, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 669.
https://doi.org/10.1182/blood.V116.21.669.669
Published: 2010
Journal Articles

Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients

Philipp Erben, MD, Benjamin Hanfstein, MD, Umang Munjal, PhD, Hannah Daikeler, MD, Mridul Agrawal, Jr., Juliana Popa, MD, Daniel Nowak, MD, Armin Leitner, MD, Dieter K Hossfeld, MD, Hans J Kolb, MD, Stefan W Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M Baerlocher, MD, Jörg Hasford, MD, Hermann Heimpel, MD, Susanne Saussele, MD, Wolf-Karsten Hofmann, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, Martin C Mueller, MD
Journal: Blood
Blood (2010) 116 (21): 671.
https://doi.org/10.1182/blood.V116.21.671.671
Published: 2010
Journal Articles

Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV

Benjamin Hanfstein, MD, Martin C. Müller, MD, Philipp Erben, MD, Susanne Schnittger, PhD, Susanne Saussele, MD, Armin Leitner, MD, Ulrike Proetel, MD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Hermann Heimpel, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD, The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 360.
https://doi.org/10.1182/blood.V116.21.360.360
Published: 2010
Journal Articles

Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV.

Susanne Saussele, MD, Nadine Pletsch, MD, Michael Lauseker, Armin Leitner, MD, Susanne Jung-Munkwitz, MD, Ulrike Proetel, MD, Martin C. Müller, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, PhD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Stefan W. Krause, MD, Christoph Nerl, MD, PhD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Leopold Balleisen, MD, Hermann Einsele, MD, Anthony D. Ho, MD, FRCPC, Christiane Falge, MD, Matthias Hänel, MD, M. Pfreundschuh, Lothar Kanz, MD, Frank Stegelmann, MD, Claus-Henning Köhne, MD, Stephan Kremers, MD, Karsten Spiekermann, MD, Steffen Koschmieder, MD, Cornelius F. Waller, MD, Martin Bentz, MD, Markus Pfirrmann, PhD, Andreas Hochhaus, Jörg Hasford, MD, Rüdiger Hehlmann, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 3411.
https://doi.org/10.1182/blood.V116.21.3411.3411
Published: 2010
Journal Articles

Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML

Armin Leitner, MD, Susanne Saussele, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, PhD, Gudrun Göhring, MD, Susanne Jung-Munkwitz, MD, Ulrike Proetel, MD, Michael Lauseker, Markus Pfirrmann, PhD, Jörg Hasford, MD, Andreas Hochhaus, Rüdiger Hehlmann, MD, The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 355.
https://doi.org/10.1182/blood.V116.21.355.355
Published: 2010
Journal Articles

Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV

Rüdiger Hehlmann, MD, Susanne Jung-Munkwitz, MD, Michael Lauseker, Martin C. Müller, MD, Armin Leitner, MD, Nadine Pletsch, MD, Ulrike Proetel, MD, Alois Gratwohl, MD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Christoph Nerl, MD, PhD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Leopold Balleisen, MD, Hermann Einsele, MD, Christiane Falge, MD, Anthony D. Ho, MD, FRCPC, Matthias Hänel, MD, Michael Pfreundschuh, MD, Lothar Kanz, MD, Frank Stegelmann, MD, Claus-Henning Köhne, MD, Stephan Kremers, CA, MD, Karsten Spiekermann, MD, Steffen Koschmieder, Cornelius F. Waller, MD, Martin Bentz, MD, Stefan W. Krause, MD, Benjamin Hanfstein, MD, Susanne Schnittger, PhD, Markus Pfirrmann, PhD, Jörg Hasford, MD, Andreas Hochhaus, Susanne Saussele, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 357.
https://doi.org/10.1182/blood.V116.21.357.357
Published: 2010
Journal Articles

Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib

Michael Schleuning, MD, Marijke Scholten, Anja van Biezen, Arnon Nagler, M.D., Jane F. Apperley, MD, Mauricette Michallet, MD, Andrew Grigg, MD, Richard T. Silver, MD, Armin Leitner, MD, Alois Gratwohl, MD, Marja Ekblom, MD, PhD, H. Jean Khoury, MD, Theo de Witte, MD, Eduardo Olavarría, MD
Journal: Blood
Blood (2010) 116 (21): 2348.
https://doi.org/10.1182/blood.V116.21.2348.2348
Published: 2010
Journal Articles

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

Clinical Trials & Observations
Susanne Saussele, Michael Lauseker, Alois Gratwohl, Dietrich W. Beelen, Donald Bunjes, Rainer Schwerdtfeger, Hans-Jochem Kolb, Anthony D. Ho, Christiane Falge, Ernst Holler, Günter Schlimok, Axel R. Zander, Renate Arnold, Lothar Kanz, Robert Dengler, Claudia Haferlach, Brigitte Schlegelberger, Markus Pfirrmann, Martin C. Müller, Susanne Schnittger, Armin Leitner, Nadine Pletsch, Andreas Hochhaus, Joerg Hasford, Rüdiger Hehlmann, for the German CML Study Group
Journal: Blood
Blood (2010) 115 (10): 1880–1885.
https://doi.org/10.1182/blood-2009-08-237115
Published: 2010
Includes: Supplemental data
Journal Articles

Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control.

Paul La Rosee, MD, Armin Leitner, MD, Philippe Martiat, MD, Thomas Klag, MD, Samina Shazi, MD, Anne Treschl, MD, Martin C Müller, MD, Thomas Schenk, MD, Benjamin Hanfstein, Andreas Hochhaus, MD
Journal: Blood
Blood (2009) 114 (22): 1119.
https://doi.org/10.1182/blood.V114.22.1119.1119
Published: 2009
Journal Articles

MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.

Mridul Agrawal, Philipp Erben, MD, Benjamin Hanfstein, Hannah Daikeler, MD, Juliana Popa, MD, Thomas Schenk, MD, Armin Leitner, MD, Richard C. Woodman, MD, Andreas Hochhaus, MD, Martin C Müller, MD
Journal: Blood
Blood (2009) 114 (22): 2615.
https://doi.org/10.1182/blood.V114.22.2615.2615
Published: 2009
Journal Articles

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

Nadine Pletsch, Susanne Saussele, Michael Lauseker, Armin Leitner, Susanne Jung-Munkwitz, Samina Shazi, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Thomas Schenk, Susanne Schnittger, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Dieter K. Hossfeld, Hans-Jochem Kolb, Stefan W Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Hermann Heimpel, Leopold Balleisen, Hermann Einsele, Anthony D. Ho, Christine Falge, Mathias Hänel, Michael Pfreundschuh, Lothar Kanz, Frank Stegelmann, Claus-Henning Köhne, Stephan Kremers, Karsten Spiekermann, Wolfgang E Berdel, Cornelius F. Waller, Martin Bentz, Joerg Hasford, Andreas Hochhaus, Rüdiger Hehlmann, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 862.
https://doi.org/10.1182/blood.V114.22.862.862
Published: 2009
Journal Articles

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Rudiger Hehlmann, Susanne Jung-Munkwitz, Michael Lauseker, Armin Leitner, Nadine Pletsch, Samina Shazi, Martin C. Müller, Claudia Haferlach, Brigitte Schlegelberger, Susanne Schnittger, PhD, Cornelius F. Waller, Andreas Neubauer, Lothar Kanz, MD, Mathias Hänel, Jiri Mayer, Frank Stegelmann, Roland Fuchs, Wolfgang E. Berdel, Leopold Balleisen, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Dieter K. Hossfeld, Hans- Jochem Kolb, Stefan W. Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Hermann Heimpel, Joerg Hasford, Andreas Hochhaus, Susanne Saussele, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 339.
https://doi.org/10.1182/blood.V114.22.339.339
Published: 2009
Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies.

Markus Pfirrmann, Susanne Saussele, Armin Leitner, MD, Nadine Pletsch, Michael Lauseker, Martin C Mueller, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, Susanne Schnittger, Gerhard Ehninger, Thomas Fischer, Dieter K Hossfeld, Hans-Jochem Kolb, Stefan W Krause, Christoph Nerl, Hans Pralle, Andreas Tobler, Hermann Heimpel, Dietrich W Beelen, Axel R Zander, Donald Bunjes, Hubert Schrezenmeier, Ulrike Feldmann, Carlheinz Mueller, Helen Baldomero, Urs Schanz, Andreas Hochhaus, Joerg Hasford, Alois Gratwohl, Ruediger Hehlmann, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 3281.
https://doi.org/10.1182/blood.V114.22.3281.3281
Published: 2009
Journal Articles

Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV.

Susanne Saussele, Michael Lauseker, Markus Pfirrmann, Armin Leitner, Nadine Pletsch, Frank Stegelmann, Anthony D Ho, Günter Schlimok, Albrecht Lindemann, Dietrich W Beelen, Alois Gratwohl, Mathias Hänel, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Philipp Erben, Susanne Schnittger, Susanne Jung-Munkwitz, Samina Shazi, Joerg Hasford, Andreas Hochhaus, Rüdiger Hehlmann, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 3287.
https://doi.org/10.1182/blood.V114.22.3287.3287
Published: 2009
Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV

Susanne Saussele, MD, Michael Lauseker, Alois Gratwohl, MD, Dominik Heim, MD, Dietrich Wilhelm Beelen, MD, Hartmut Döhner, MD, Rainer Schwerdtfeger, MD, Anthony D. Ho, MD, Hans-Jochem Kolb, MD, Markus Pfirrmann, PhD, Martin C. Müller, MD, Armin Leitner, MD, Ulrike Proetel, MD, Elena Kovalevskaya, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, Joerg Hasford, MD, Andreas Hochhaus, MD, Ruediger Hehlmann, MD
Journal: Blood
Blood (2008) 112 (11): 448.
https://doi.org/10.1182/blood.V112.11.448.448
Published: 2008
Journal Articles

Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV

Martin C. Müller, MD, Benjamin Hanfstein, MD, Philipp Erben, MD, Susanne Schnittger, PhD, Susanne Saussele, MD, Armin Leitner, MD, Ulrike Proetel, MD, Michael Lauseker, Markus Pfirrmann, PhD, Gerhard Ehninger, MD, Thomas Fischer, MD, Joerg Hasford, MD, Dieter K. Hossfeld, MD, PhD, Hans Jochem Kolb, MD, Stefan W Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Alois Gratwohl, MD, Andreas Tobler, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD, The German CML Study Group
Journal: Blood
Blood (2008) 112 (11): 333.
https://doi.org/10.1182/blood.V112.11.333.333
Published: 2008
Journal Articles

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

Ruediger Hehlmann, MD, Susanne Saussele, MD, Michael Lauseker, Ulrike Proetel, MD, Elena Kovalevskaya, MD, Armin Leitner, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, Martin C Müller, MD, Benjamin Hanfstein, MD, Markus Pfirrmann, PhD, Gerhard Ehninger, Thomas Fischer, MD, Joerg Hasford, MD, Andreas Hochhaus, MD, Dieter K. Hossfeld, MD, PhD, Hans- Jochem Kolb, MD, Stefan W Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Alois Gratwohl, Andreas Tobler, MD, Hermann Heimpel, MD, The German CML Study Group
Journal: Blood
Blood (2008) 112 (11): 184.
https://doi.org/10.1182/blood.V112.11.184.184
Published: 2008